159 related articles for article (PubMed ID: 10491371)
1. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.
Kugiyama K; Ota Y; Takazoe K; Moriyama Y; Kawano H; Miyao Y; Sakamoto T; Soejima H; Ogawa H; Doi H; Sugiyama S; Yasue H
Circulation; 1999 Sep; 100(12):1280-4. PubMed ID: 10491371
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention.
Liu PY; Li YH; Tsai WC; Chao TH; Tsai LM; Wu HL; Chen JH
Eur Heart J; 2003 Oct; 24(20):1824-32. PubMed ID: 14563341
[TBL] [Abstract][Full Text] [Related]
3. Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease.
Fichtlscherer S; Kaszkin M; Breuer S; Dimmeler S; Zeiher AM
Clin Sci (Lond); 2004 May; 106(5):511-7. PubMed ID: 14686876
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.
Kugiyama K; Ota Y; Sugiyama S; Kawano H; Doi H; Soejima H; Miyamoto S; Ogawa H; Takazoe K; Yasue H
Am J Cardiol; 2000 Oct; 86(7):718-22. PubMed ID: 11018189
[TBL] [Abstract][Full Text] [Related]
5. Increase in plasma levels of secretory type II phospholipase A(2) in patients with coronary spastic angina.
Kugiyama K; Ota Y; Kawano H; Soejima H; Ogawa H; Sugiyama S; Doi H; Yasue H
Cardiovasc Res; 2000 Jul; 47(1):159-65. PubMed ID: 10869542
[TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.
O'Donoghue ML; Mallat Z; Morrow DA; Benessiano J; Sloan S; Omland T; Solomon SD; Braunwald E; Tedgui A; Sabatine MS
Clin Chem; 2011 Sep; 57(9):1311-7. PubMed ID: 21784767
[TBL] [Abstract][Full Text] [Related]
7. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease.
Koenig W; Vossen CY; Mallat Z; Brenner H; Benessiano J; Rothenbacher D
Eur Heart J; 2009 Nov; 30(22):2742-8. PubMed ID: 19666896
[TBL] [Abstract][Full Text] [Related]
8. Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans.
Nijmeijer R; Lagrand WK; Baidoshvili A; Lubbers YT; Hermens WT; Meijer CJ; Visser CA; Hack CE; Niessen HW
Cardiovasc Res; 2002 Jan; 53(1):138-46. PubMed ID: 11744022
[TBL] [Abstract][Full Text] [Related]
9. Relation of secretory phospholipase A(2) and high-sensitivity C-reactive protein to Chlamydia pneumoniae infection in acute coronary syndromes.
Miya N; Oguchi S; Watanabe I; Kanmatsuse K
Circ J; 2004 Jul; 68(7):628-33. PubMed ID: 15226626
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.
Packard CJ; O'Reilly DS; Caslake MJ; McMahon AD; Ford I; Cooney J; Macphee CH; Suckling KE; Krishna M; Wilkinson FE; Rumley A; Lowe GD
N Engl J Med; 2000 Oct; 343(16):1148-55. PubMed ID: 11036120
[TBL] [Abstract][Full Text] [Related]
11. Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study.
Wootton PT; Drenos F; Cooper JA; Thompson SR; Stephens JW; Hurt-Camejo E; Wiklund O; Humphries SE; Talmud PJ
Hum Mol Genet; 2006 Jan; 15(2):355-61. PubMed ID: 16368710
[TBL] [Abstract][Full Text] [Related]
12. Secretory type II phospholipase A2 in culprit coronary lesions is associated with myocardial infarction.
Nijmeijer R; Meuwissen M; Krijnen PA; van der Wal A; Piek JJ; Visser CA; Hack CE; Niessen HW
Eur J Clin Invest; 2008 Apr; 38(4):205-10. PubMed ID: 18339001
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes.
Hartford M; Wiklund O; Mattsson Hultén L; Persson A; Karlsson T; Herlitz J; Caidahl K
J Intern Med; 2007 Nov; 262(5):526-36. PubMed ID: 17908161
[TBL] [Abstract][Full Text] [Related]
14. Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease.
Divchev D; Grothusen C; Luchtefeld M; Thoenes M; Onono F; Koch R; Drexler H; Schieffer B
Eur Heart J; 2008 Aug; 29(16):1956-65. PubMed ID: 18565968
[TBL] [Abstract][Full Text] [Related]
15. Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.
Breitling LP; Koenig W; Fischer M; Mallat Z; Hengstenberg C; Rothenbacher D; Brenner H
PLoS One; 2011; 6(7):e22318. PubMed ID: 21799821
[TBL] [Abstract][Full Text] [Related]
16. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study.
Mallat Z; Benessiano J; Simon T; Ederhy S; Sebella-Arguelles C; Cohen A; Huart V; Wareham NJ; Luben R; Khaw KT; Tedgui A; Boekholdt SM
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1177-83. PubMed ID: 17303774
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death.
May HT; Horne BD; Anderson JL; Wolfert RL; Muhlestein JB; Renlund DG; Clarke JL; Kolek MJ; Bair TL; Pearson RR; Sudhir K; Carlquist JF
Am Heart J; 2006 Nov; 152(5):997-1003. PubMed ID: 17070179
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Boekholdt SM; Keller TT; Wareham NJ; Luben R; Bingham SA; Day NE; Sandhu MS; Jukema JW; Kastelein JJ; Hack CE; Khaw KT
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):839-46. PubMed ID: 15692105
[TBL] [Abstract][Full Text] [Related]
20. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease.
Fukushima H; Kugiyama K; Sugiyama S; Honda O; Koide S; Nakamura S; Kawano H; Soejima H; Miyamoto S; Yoshimura M; Sakamoto T; Ogawa H
Am J Cardiol; 2001 Dec; 88(12):1370-3. PubMed ID: 11741554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
